Navigation Links
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
Date:8/8/2011

and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2010 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events. INSMED INCORPORATEDConsolidated Balance Sheets (Unaudited)(in thousands, except share and per share data)June 30,

December 31,2011

2010AssetsCurrent assets:   Cash and cash equivalents

$
9,839

$
,743  Short-term investments

82,123

97,306  Accounts receivable, net

303

471  Prepaid expenses

354

277Total current assets

92,619

108,797Certificate of deposit

2,085

2,176In-process research and development

77,900

77,900Goodwill

6,290

6,290Deposits

378

-Fixed assets, net

1,016

1,102Total assets

$
80,288

$
96,265Liabilities and stockholders' equityCurrent liabilities:   Accounts payable

$
,921

$
,450  Accrued expenses

1,162

1,256  Deferred rent

150

150  Capital lease obligations, current

64

81  Deferred revenue

195

402Total current liabilities

3,492

3,339Capital lease obligations, long-term58

83Total liabilities

3,550

3,422Stockholders' equity: Common stock; $.01 par value; authorized shares   500,000,000; issued and outstanding shares, 24,833,301 in 2011 and 15,653,734 in 2010

2
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
7. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
9. Insmed to Host Third Quarter 2010 Conference Call
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
11. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... ALISO VIEJO , Kalifornien, 20. Mai ... heute bekannt, dass das Unternehmen die CE-Kennzeichnung ... Implantate zur Embolisation von Aneurysmen erhalten hat. ... in Europa bereits mit der kontrollierten Einführung ... Profil bietet die SL-Produktfamilie auch ein verbessertes ...
(Date:5/20/2013)... Enrollment of patients with Type 2 diabetes ... trial of product candidate NewMet ™, a delayed-release ... 2 diabetes. Elcelyx expects to complete enrollment of 240 ... of the trial,s primary endpoint of change in fasting ... read-out for long-term glucose lowering and weight benefits is ...
(Date:5/20/2013)... 20, 2013  AbbVie (NYSE: ABBV ... 3 clinical study called SONAR (Study Of Diabetic ... the investigational compound atrasentan - when added to standard ... patients with stage 2 to 4 chronic kidney ... a large, multinational, double-blind, placebo-controlled clinical study that ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
(Date:5/20/2013)... (PRWEB) May 20, 2013 Rapid Financial ... providers of short-term working capital to small businesses, today ... , Launching on May 20, the objective of ... business owners via an unexpected medium and through memorable ... and a partnership with the company. By extension, ...
(Date:5/20/2013)... May 20, 2013 VHA Inc., ... leader in automated, provider-led population health improvement, announced ... effect change and successfully pursue population health ... and technology to accelerate the transition to value-based ... IMPERATIVTM performance improvement suite of services, the offering ...
(Date:5/20/2013)... St. Lucie, FL (PRWEB) May 20, 2013 ... to be an official race location for the best long ... the city of Port City Lucie a venue of raising ... way of showcasing our city. The IDSA is the authority ... sanctioning help, they will insure our event is safe and ...
(Date:5/20/2013)... of anabolic-androgenic steroids and reduced mental health later in ... study on elite male strength athletes that researchers from ... British Journal of Sports Medicine . Twenty per cent ... , The study is published by CERA, which ... research on addiction. Together with colleagues from Sahlgrenska University ...
(Date:5/20/2013)... at Lund University in Sweden have mapped the ... disease. No studies have previously examined whether different ... looked at coronary heart disease, ischemic stroke, peripheral ... individuals whose siblings and parents have suffered different ... that heredity is highest for atherosclerosis of the ...
Breaking Medicine News(10 mins):Health News:RapidAdvance Turns to National Television Advertising Campaign to Reach Small Business Owners 2Health News:RapidAdvance Turns to National Television Advertising Campaign to Reach Small Business Owners 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4
... , , ARLINGTON, ... Health and Human Services Office of Inspector General (OIG) ignored ... including complex rehab, to seniors and people with disabilities who ... the Medicare Program: Supplier Acquisition Costs and Services" and dated ...
... OKLAHOMA CITY, Sept. 3 Surgical Hospital of ... partnered with Surgical Care Affiliates (SCA), one of the country,s ... is a state of the art hospital providing surgical services ... pain management, podiatry and orthopedics. SCA and a number of ...
... done to protect young knees, ankles and shoulders, researcher says ... all high school sports injuries are bad enough to keep a ... the pack in severe injuries, a new U.S. study finds. , ... girls experienced a greater rate of severe injury than boys in ...
... worldunderstand and prepare for contagious outbreaks, the National Institutes ... adds new research expertise to increase its capacity to ... inform public health officials and policymakers. In ... and infected people around the world. In 2003, a ...
... delaying needed care ends up raising health-care costs, study ... -- Patients who don,t trust the health-care system are ... health and raising overall health care costs, a new ... majority of whom were black, about their attitudes toward ...
... , , , , ... entered into a definitive agreement under which Embla will acquire Covidien,s ... the Sandman(TM) brand name. Financial terms of the transaction were ... conditions. , , The combined entity will form ...
Cached Medicine News:Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:Surgical Hospital of Oklahoma to Partner with Surgical Care Affiliates 2Health News:High School Sports Put Players at Risk for Severe Injuries 2Health News:New grants expand US infectious disease modeling effort 2Health News:New grants expand US infectious disease modeling effort 3Health News:Mistrust May Cause People to Put Off Treatment 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2
This portable resource provides definitions for medical acronyms and abbreviations....
English and Spanish translations of all medical terms and phrases used in clinician-patient interactions....
... This Mobile Solution (Palm OS) makes ... patient visit information functionality of the ... (PDA). You'll save time and have access ... at your desktop - review appointment schedules, ...
Preferred Health Resourses Practice Management System is called Remedy. The PDA version is Remedy for the Palm. It is a data capture program for your medical billing....
Medicine Products: